前往化源商城

品牌现货直购
供应商:我要出现这里








查看所有供应商和价格请点击:

50-78-2生产厂家

50-78-2价格

50-78-2

50-78-2结构式
50-78-2结构式

化源商城直购

中文名 2-(乙酰氧基)苯甲酸
英文名 acetylsalicylic acid
中文别名 邻乙酰水杨酸
乙酰水杨酸
2-乙酰氧基苯甲酸
阿司匹林
阿斯匹林
O-乙酰基水杨酸
英文别名 Adiro
2-Acetoxybenzoic acid,O-Acetylsalicyl
Acetyonyl
EINECS 200-064-1
ronal
Miniasal
Acetoxybenzoic acid
Melhoral
Aspr
A.S.A.
o-Acetylsalicylic acid
Triaminicin
ASA
Acesan
Asatard
Acetysalicylic acid
Aspro
Rhodine NC RP
2-Carboxyphenyl acetate
O-acetyl salicylic acid
Aspropharm
o-(Acetyloxy)benzoic Acid
Xaxa
Salicylic acid, acetyl-
2-Acetoxybenzoic acid,O-Acetylsalicylic acid,ASA
Aspirin
Cardioaspirina
Toldex
acetyl salicylic acid
Acetard
Bayer
2-Acetoxybenzenecarboxylic acid
Salospir
ACETYLSALICYLIC ACID
ECM
Novid
2-(Acetyloxy)benzoic acid
2-Acetyloxybenzoic acid
Benzoic acid, 2-(acetyloxy)-
Aspec
Tasprin
Doril
2-Acetoxybenzoic acid
MFCD00002430
Acetyl-SAL
QVR BOV1
描述 Aspirin是非选择性和不可逆的 COX-1 和 COX-2 抑制剂,IC50 分别为5,210 μg/mL。
相关类别
靶点

COX-1:27.75 μM (IC50)

COX-2:1.17 mM (IC50)

体外研究 阿司匹林和其他非类固醇抗炎药物可抑制环氧合酶(COX)的活性,从而导致前列腺素(PGs)的形成,引起炎症,肿胀,疼痛和发烧[2]。阿司匹林乙酰化环氧合酶-1(COX-1)的丝氨酸-530,从而阻止血小板中血栓素A的合成并减少血小板聚集。这种作用机制解释了阿司匹林对预防冠状动脉和脑血管血栓形成的作用。阿司匹林在抑制COX-2活性方面效果较差。阿司匹林和水杨酸通过干扰CCAAT /增强子结合蛋白β(C/EBPbeta)与COX-2启动子/增强子上的同源位点的结合来抑制COX-2蛋白表达[3]。阿司匹林抑制NF-κB的活化。这种抑制作用可防止NF-κB抑制剂1κB的降解,因此NF-κB保留在细胞质中。阿司匹林还抑制转染的T细胞中lgκ增强子和人类免疫缺陷病毒(HIV)长末端重复序列(LTR)的NF-κB依赖性转录[4]。在人关节软骨细胞中,阿司匹林抑制COX-1和COX-2的IC50值分别为3.57μM和29.3μM[5]。
细胞实验 从没有关节疾病的供体的关节软骨中分离软骨细胞。未刺激和白细胞介素1(IL-1)刺激的软骨细胞被用作研究药物对COX-1和COX-2的影响的模型。将细胞与载体或药物(Asprin)一起孵育;除去上清液,通过酶免疫测定法测定每个样品中前列腺素E2(PGE2)的水平。通过线性回归分析,通过不同浓度的测试物质降低PGE2含量来计算IC50 [5]。
参考文献

[1]. Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and induciblecyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7.

[2]. Vane JR, et al. The mechanism of action of aspirin. Thromb Res. 2003 Jun 15;110(5-6):255-8.

[3]. Wu KK, et al. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12.

[4]. Kopp E, et al. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994 Aug 12;265(5174):956-9.

[5]. Blanco FJ, et al. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73.

密度 1.3±0.1 g/cm3
沸点 321.4±25.0 °C at 760 mmHg
熔点 134-136 °C(lit.)
分子式 C9H8O4
分子量 180.157
闪点 131.2±16.7 °C
精确质量 180.042252
PSA 63.60000
LogP 1.19
外观性状 白色至灰白色结晶粉末
蒸汽压 0.0±0.7 mmHg at 25°C
折射率 1.551
储存条件

1.生产设备应密闭,车间内保持良好通风状态。

2.避光、密闭于干燥处保存。

稳定性

1.口服有毒,大量使用应穿适当的防护服。

水溶解性 3.3 g/L (20 ºC)
分子结构

1、 摩尔折射率:44.52

2、 摩尔体积(cm3/mol):139.5

3、 等张比容(90.2K):370.9

4、 表面张力(dyne/cm):49.8

5、 极化率(10-24cm3):17.65

计算化学

1、 疏水参数计算参考值(XlogP):1.2

2、 氢键供体数量:1

3、 氢键受体数量:4

4、 可旋转化学键数量:3

5、 互变异构体数量:

6、 拓扑分子极性表面积(TPSA):63.6

7、 重原子数量:13

8、 表面电荷:0

9、 复杂度:212

10、同位素原子数量:0

11、确定原子立构中心数量:0

12、不确定原子立构中心数量:0

13、确定化学键立构中心数量:0

14、不确定化学键立构中心数量:0

15、共价键单元数量:1

更多

1. 性状:白色针状或片状结晶。无气味。微带酸味在干燥空气中稳定,在潮湿空气中逐渐水解成水杨酸和乙酸。

2. 密度(g/mL,25/4℃):1.1872154

3.相对密度(20℃,4℃):1.40

4. 熔点(ºC):135

5. 沸点(ºC,常压):未确定

6. 沸点(ºC, 5.2kPa):未确定

7. 折射率:未确定

8. 闪点(ºC):未确定

9. 比旋光度(º ):未确定

10. 自燃点或引燃温度(ºC):未确定

11. 蒸气压(kPa,25ºC):未确定

12. 饱和蒸气压(kPa,60ºC):未确定

13. 燃烧热(KJ/mol):未确定

14. 临界温度(ºC):未确定

15. 临界压力(KPa):未确定

16. 油水(辛醇/水)分配系数的对数值:未确定

17. 爆炸上限(%,V/V):未确定

18. 爆炸下限(%,V/V):未确定

19. 溶解性: 溶于乙醇、乙醚,微溶于水。


模块1. 化学品
1.1 产品标识符
: 乙酰水杨酸
产品名称
: Vetec
1.2 鉴别的其他方法
无数据资料
1.3 有关的确定了的物质或混合物的用途和建议不适合的用途
仅用于研发。不作为药品、家庭或其它用途。

模块2. 危险性概述
2.1 GHS-分类
急性毒性, 经口 (类别 3)
皮肤刺激 (类别 2)
眼睛刺激 (类别 2A)
特异性靶器官系统毒性(一次接触) (类别 3)
2.2 GHS 标记要素,包括预防性的陈述
象形图
警示词危险
危险申明
H301吞咽会中毒
H315造成皮肤刺激。
H319造成严重眼刺激。
H335可能引起呼吸道刺激。
警告申明
预防措施
P261避免吸入粉尘/烟/气体/烟雾/蒸气/喷雾.
P264操作后彻底清洁皮肤。
P270使用本产品时不要进食、饮水或吸烟。
P271只能在室外或通风良好之处使用。
P280穿戴防护手套/ 眼保护罩/ 面部保护罩。
事故响应
P301 + P310如果吞下去了: 立即呼救解毒中心或医生。
P302 + P352如果皮肤接触:用大量肥皂和水清洗。
P304 + P340如吸入: 将患者移到新鲜空气处休息,并保持呼吸舒畅的姿势。
P305 + P351 + P338如与眼睛接触,用水缓慢温和地冲洗几分钟。如戴隐形眼镜并可方便地取
出,取出隐形眼镜,然后继续冲洗.
P312如感觉不适,呼救中毒控制中心或医生.
P321具体处置(见本标签上提供的急救指导)。
P330漱口。
P332 + P313如觉皮肤刺激:求医/就诊。
P337 + P313如仍觉眼睛刺激:求医/就诊。
P362脱掉沾污的衣服,清洗后方可再用。
安全储存
P403 + P233存放于通风良的地方。 保持容器密闭。
P405存放处须加锁。
废弃处置
P501将内容物/ 容器处理到得到批准的废物处理厂。
2.3 其它危害物 - 无

模块3. 成分/组成信息
3.1 物 质
: C9H8O4
分子式
: 180.16 g/mol
分子量
组分浓度或浓度范围
O-Acetylsalicylic acid
<=100%
化学文摘登记号(CAS50-78-2
No.)200-064-1
EC-编号

模块4. 急救措施
4.1 必要的急救措施描述
一般的建议
请教医生。 向到现场的医生出示此安全技术说明书。
吸入
如果吸入,请将患者移到新鲜空气处。 如呼吸停止,进行人工呼吸。 请教医生。
皮肤接触
用肥皂和大量的水冲洗。 请教医生。
眼睛接触
用大量水彻底冲洗至少15分钟并请教医生。
食入
切勿给失去知觉者通过口喂任何东西。 用水漱口。 请教医生。
4.2 主要症状和影响,急性和迟发效应
据我们所知,此化学,物理和毒性性质尚未经完整的研究。
4.3 及时的医疗处理和所需的特殊处理的说明和指示
无数据资料

模块5. 消防措施
5.1 灭火介质
灭火方法及灭火剂
用水雾,抗乙醇泡沫,干粉或二氧化碳灭火。
5.2 源于此物质或混合物的特别的危害
碳氧化物
5.3 给消防员的建议
如必要的话,戴自给式呼吸器去救火。
5.4 进一步信息
无数据资料

模块6. 泄露应急处理
6.1 作业人员防护措施、防护装备和应急处置程序
使用个人防护用品。 避免粉尘生成。 避免吸入蒸气、烟雾或气体。 保证充分的通风。
人员疏散到安全区域。 避免吸入粉尘。
6.2 环境保护措施
不要让产品进入下水道。
6.3 泄漏化学品的收容、清除方法及所使用的处置材料
收集和处置时不要产生粉尘。 扫掉和铲掉。 放入合适的封闭的容器中待处理。
6.4 参考其他部分
丢弃处理请参阅第13节。

模块7. 操作处置与储存
7.1 安全操作的注意事项
避免接触皮肤和眼睛。 避免形成粉尘和气溶胶。
在有粉尘生成的地方,提供合适的排风设备。
7.2 安全储存的条件,包括任何不兼容性
贮存在阴凉处。 使容器保持密闭,储存在干燥通风处。
7.3 特定用途
无数据资料

模块8. 接触控制和个体防护
8.1 容许浓度
最高容许浓度
组分化学文摘登值容许浓度基准
记号(CAS
No.)
O-Acetylsalicylic50-78-2PC-5 mg/m3工作场所有害因素职业接触限值 -
acidTWA化学有害因素
8.2 暴露控制
适当的技术控制
根据良好的工业卫生和安全规范进行操作。 休息前和工作结束时洗手。
个体防护设备
眼/面保护
带有防护边罩的安全眼镜符合 EN166要求请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟)
检测与批准的设备防护眼部。
皮肤保护
戴手套取 手套在使用前必须受检查。
请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品.
使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手
所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。
完全接触
物料: 丁腈橡胶
最小的层厚度 0.11 mm
溶剂渗透时间: 480 min
测试过的物质Dermatril® (KCL 740 / Z677272, 规格 M)
飞溅保护
物料: 丁腈橡胶
最小的层厚度 0.11 mm
溶剂渗透时间: 480 min
测试过的物质Dermatril® (KCL 740 / Z677272, 规格 M)
, 测试方法 EN374
如果以溶剂形式应用或与其它物质混合应用,或在不同于EN
374规定的条件下应用,请与EC批准的手套的供应商联系。
这个推荐只是建议性的,并且务必让熟悉我们客户计划使用的特定情况的工业卫生学专家评估确认才可.
这不应该解释为在提供对任何特定使用情况方法的批准.
身体保护
全套防化学试剂工作服, 防护设备的类型必须根据特定工作场所中的危险物的浓度和数量来选择。
呼吸系统防护
如须暴露于有害环境中,请使用P95型(美国)或P1型(欧盟 英国
143)防微粒呼吸器。如需更高级别防护,请使用OV/AG/P99型(美国)或ABEK-P2型 (欧盟 英国 143)
防毒罐。
呼吸器使用经过测试并通过政府标准如NIOSH(US)或CEN(EU)的呼吸器和零件。

模块9. 理化特性
9.1 基本的理化特性的信息
a) 外观与性状
形状: 粉末
颜色: 白色
b) 气味
无数据资料
c) 气味阈值
无数据资料
d) pH值
3.5 在 2.5 g/l 在 20 °C
e) 熔点/凝固点
熔点/凝固点: 138 - 140 °C
f) 沸点、初沸点和沸程
无数据资料
g) 闪点
250 °C - 闭杯
h) 蒸发速率
无数据资料
i) 易燃性(固体,气体)
无数据资料
j) 高的/低的燃烧性或爆炸性限度 无数据资料
k) 蒸气压
无数据资料
l) 蒸汽密度
无数据资料
m) 密度/相对密度
无数据资料
n) 水溶性
无数据资料
o) n-辛醇/水分配系数
辛醇--水的分配系数的对数值: 1.19
p) 自燃温度
无数据资料
q) 分解温度
无数据资料
r) 粘度
无数据资料

模块10. 稳定性和反应活性
10.1 反应性
无数据资料
10.2 稳定性
无数据资料
10.3 危险反应
无数据资料
10.4 应避免的条件
加热。 暴露在光照下。
10.5 不相容的物质
强氧化剂, 强酸, 强碱
10.6 危险的分解产物

模块11. 毒理学资料
11.1 毒理学影响的信息
急性毒性
半数致死剂量 (LD50) 经口 - 大鼠 - 1,500 mg/kg
半数致死剂量 (LD50) 腹膜内的 - 大鼠 - 340 mg/kg
半数致死剂量 (LD50) 腹膜内的 - 小鼠 - 167 mg/kg
皮肤刺激或腐蚀
无数据资料
眼睛刺激或腐蚀
无数据资料
呼吸道或皮肤过敏
无数据资料
生殖细胞致突变性
无数据资料
致癌性
IARC:
此产品中没有大于或等于 0。1%含量的组分被 IARC鉴别为可能的或肯定的人类致癌物。
生殖毒性
无数据资料
从实验动物的结果看,过度接触能导致生殖紊乱
特异性靶器官系统毒性(一次接触)
吸入 - 可能引起呼吸道刺激。
特异性靶器官系统毒性(反复接触)
无数据资料
吸入危险
无数据资料
潜在的健康影响
吸入吸入可能有害。 引起呼吸道刺激。
摄入误吞对人体有害。
皮肤通过皮肤吸收可能有害。 造成皮肤刺激。
眼睛造成严重眼刺激。
接触后的征兆和症状
据我们所知,此化学,物理和毒性性质尚未经完整的研究。
附加说明
化学物质毒性作用登记: 无数据资料

模块12. 生态学资料
12.1 生态毒性
对鱼类的毒性半数致死浓度(LC50) - 高体雅罗鱼 (金雅罗鱼) - > 1,000 mg/l - 48 h
对水蚤和其他水生无脊半数效应浓度(EC50) - 水蚤 - > 100 mg/l - 48 h
椎动物的毒性
细菌毒性半数致死浓度(LC50) - 细菌 - > 10,000 mg/l - 48 h
12.2 持久性和降解性
生物降解能力
备注: 预计可生物降解
12.3 潜在的生物累积性
无数据资料
12.4 土壤中的迁移性
无数据资料
12.5 PBT 和 vPvB的结果评价
无数据资料
12.6 其它不良影响
无数据资料

模块13. 废弃处置
13.1 废物处理方法
产品
将剩余的和不可回收的溶液交给有许可证的公司处理。
与易燃溶剂相溶或者相混合,在备有燃烧后处理和洗刷作用的化学焚化炉中燃烧
受污染的容器和包装
按未用产品处置。

模块14. 运输信息
14.1 联合国危险货物编号
欧洲陆运危规: -国际海运危规: -国际空运危规: -
14.2 联合国运输名称
欧洲陆运危规: 非危险货物
国际海运危规: 非危险货物
国际空运危规: 非危险货物
14.3 运输危险类别
欧洲陆运危规: -国际海运危规: -国际空运危规: -
14.4 包裹组
欧洲陆运危规: -国际海运危规: -国际空运危规: -
14.5 环境危险
欧洲陆运危规: 否国际海运危规国际空运危规: 否
海洋污染物(是/否): 否
14.6 对使用者的特别提醒
无数据资料


模块 15 - 法规信息
N/A


模块16 - 其他信息
N/A

毒理学数据:

急性毒性:

口腔 LD50 700mg/kg(dog)

1075mg/kg(guinea pig)

3500mg/kg(ham)

1750mg/kg(mam)

250mg/kg(mus)

200mg/kg(rat)

1010mg/kg(rbt)

LDLo 104mg/kg(chd)

主要的刺激性影响:

在皮肤上面:刺激皮肤和粘膜。

在眼睛上面:刺激的影响

致敏作用:没有已知的敏化作用。

生态学数据:

总括注解

水危害级别1(德国规例)(通过名单进行自我评估)该物质对水有稍微危害的。

不要让未稀释或大量的产品接触地下水、水道或污水系统。

若无政府许可,勿将材料排入周围环境。

CHEMICAL IDENTIFICATION

RTECS NUMBER :
VO0700000
CHEMICAL NAME :
Salicylic acid, acetate
CAS REGISTRY NUMBER :
50-78-2
BEILSTEIN REFERENCE NO. :
0779271
LAST UPDATED :
199712
DATA ITEMS CITED :
105
MOLECULAR FORMULA :
C9-H8-O4
MOLECULAR WEIGHT :
180.17
WISWESSER LINE NOTATION :
QVR BOV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
10 mg/kg/1D-I
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - acute pulmonary edema Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - urine volume decreased
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
857 mg/kg
TOXIC EFFECTS :
Behavioral - coma Lungs, Thorax, or Respiration - respiratory stimulation
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
525 mg/kg/5D-I
TOXIC EFFECTS :
Liver - hepatitis (hepatocellular necrosis), diffuse
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
480 mg/kg/5D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Biochemical - Metabolism (Intermediary) - other
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
1625 mg/kg
TOXIC EFFECTS :
Behavioral - coma Nutritional and Gross Metabolic - body temperature increase
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - infant
DOSE/DURATION :
120 mg/kg
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - respiratory stimulation Kidney, Ureter, Bladder - hematuria Nutritional and Gross Metabolic - dehydration
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
104 mg/kg
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - acute pulmonary edema Gastrointestinal - nausea or vomiting Blood - hemorrhage
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
39 mg/kg/13D-I
TOXIC EFFECTS :
Liver - hepatitis (hepatocellular necrosis), diffuse
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
669 mg/kg/11D
TOXIC EFFECTS :
Liver - liver function tests impaired
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
2880 mg/kg/8W
TOXIC EFFECTS :
Sense Organs and Special Senses (Ear) - tinnitus Gastrointestinal - nausea or vomiting Gastrointestinal - decreased motility or constipation
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
800 mg/kg
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Musculoskeletal - other changes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
480 mg/kg/7D-I
TOXIC EFFECTS :
Sense Organs and Special Senses (Ear) - tinnitus Behavioral - somnolence (general depressed activity) Gastrointestinal - other changes
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
294 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Rectal
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
4550 mg/kg
TOXIC EFFECTS :
Brain and Coverings - encephalitis Behavioral - coma Cardiac - arrhythmias (including changes in conduction)
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
200 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
340 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Rectal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
790 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
250 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
167 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1020 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
700 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Lungs, Thorax, or Respiration - respiratory depression
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
681 mg/kg
TOXIC EFFECTS :
Behavioral - analgesia
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
1010 mg/kg
TOXIC EFFECTS :
Behavioral - changes in motor activity (specific assay)
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
1075 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Behavioral - tremor
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - hamster
DOSE/DURATION :
3500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - species unspecified
DOSE/DURATION :
1750 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
200 mg/kg/4D-I
TOXIC EFFECTS :
Gastrointestinal - ulceration or bleeding from stomach
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
8127 mg/kg/43W-C
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes in urine composition
TYPE OF TEST :
TCLo - Lowest published toxic concentration
ROUTE OF EXPOSURE :
Inhalation
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
25 mg/m3/4H/17W-I
TOXIC EFFECTS :
Brain and Coverings - recordings from specific areas of CNS Blood - change in clotting factors Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
9500 mg/kg/3W-I
TOXIC EFFECTS :
Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
700 mg/kg
SEX/DURATION :
female 35-36 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
546 mg/kg
SEX/DURATION :
female 37-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - other postnatal measures or effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
546 mg/kg
SEX/DURATION :
female 37-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
17550 mg/kg
SEX/DURATION :
female 12-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
100 mg/kg
SEX/DURATION :
female 37 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - other neonatal measures or effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
17280 mg/kg
SEX/DURATION :
female 1-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Effects on Newborn - Apgar score (human only)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
189 mg/kg
SEX/DURATION :
female 12-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
1200 mg/kg
SEX/DURATION :
female 20 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1 gm/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2100 mg/kg
SEX/DURATION :
male 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - testes, epididymis, sperm duct
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
500 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
200 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
10 mg/kg
SEX/DURATION :
female 22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - live birth index (measured after birth)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
500 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
125 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1 gm/kg
SEX/DURATION :
female 3 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1800 mg/kg
SEX/DURATION :
male 12 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
380 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
500 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
500 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
500 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
300 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
3500 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intrauterine
DOSE :
2 mg/kg
SEX/DURATION :
female 4 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1200 mg/kg
SEX/DURATION :
female 8-9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
800 mg/kg
SEX/DURATION :
female 17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
19200 mg/kg
SEX/DURATION :
female 6-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - other neonatal measures or effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2500 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
500 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
3200 mg/kg
SEX/DURATION :
female 23-30 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - respiratory system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
3 gm/kg
SEX/DURATION :
female 20-34 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
300 mg/kg
SEX/DURATION :
female 10-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
800 mg/kg
SEX/DURATION :
female 8-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1800 mg/kg
SEX/DURATION :
female 8-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1750 mg/kg
SEX/DURATION :
female 6-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
600 mg/kg
SEX/DURATION :
female 2 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
11250 mg/kg
SEX/DURATION :
female 16-30 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
Sister chromatid exchange

MUTATION DATA

TYPE OF TEST :
Cytogenetic analysis
TEST SYSTEM :
Rodent - hamster Lung
REFERENCE :
GMCRDC Gann Monograph on Cancer Research. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013) No. 11- 1971- Volume(issue)/page/year: 27,95,1981 *** REVIEWS *** ACGIH TLV-TWA 5 mg/m3 DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 TOXICOLOGY REVIEW BCSTB5 Biochemical Society Transactions. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1973- Volume(issue)/page/year: 2,695,1974 TOXICOLOGY REVIEW DICPBB Drug Intelligence and Clinical Pharmacy. (POB 42435, Cincinnati, OH 45242) V.3- 1969- Volume(issue)/page/year: 9,350,1975 TOXICOLOGY REVIEW DICPBB Drug Intelligence and Clinical Pharmacy. (POB 42435, Cincinnati, OH 45242) V.3- 1969- Volume(issue)/page/year: 8,690,1974 TOXICOLOGY REVIEW PLMJAP Pahlavi Medical Journal. (Shiraz, Iran) V.1-9, 1970-78. Volume(issue)/page/year: 6,160,1975 TOXICOLOGY REVIEW JPHAA3 Journal of the American Pharmaceutical Association. (Washington, DC) V.1-28, 1912-39; New series: V.1-17, 1961-77. Volume(issue)/page/year: NS16,147,1976 TOXICOLOGY REVIEW AUHPAI Australian Journal of Hospital Pharmacy. (B.R. Miller, POB 125, Heidelberg, Vic., Australia) V.1- 1971- Volume(issue)/page/year: 3(3),100,1973 TOXICOLOGY REVIEW JRPMAP Journal of Reproductive Medicine. (2 Jacklynn Ct., St. Louis, MO 63132) V.3- 1969- Volume(issue)/page/year: 12,27,1974 TOXICOLOGY REVIEW CLCHAU Clinical Chemistry (Winston-Salem, NC). (American Assoc. for Clinical Chemistry, 1725 K St., NW, Washington, DC 20006) V.1- 1955- Volume(issue)/page/year: 19,361,1973 TOXICOLOGY REVIEW AJMEAZ American Journal of Medicine. (Technical Pub., 875 Third Ave., New York, NY 10022) V.1- 1946- Volume(issue)/page/year: 38,409,1965 TOXICOLOGY REVIEW ATXKA8 Archiv fuer Toxikologie. (Berlin, Fed. Rep. Ger.) V.15-31, 1954-74. For publisher information, see ARTODN. Volume(issue)/page/year: 28,135,1971 TOXICOLOGY REVIEW AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1908- Volume(issue)/page/year: 141,358,1981 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-AUSTRALIA:TWA 5 mg/m3 JAN 1993 OEL-BELGIUM:TWA 5 mg/m3 JAN 1993 OEL-DENMARK:TWA 5 mg/m3 JAN 1993 OEL-THE NETHERLANDS:TWA 5 mg/m3 JAN 1993 OEL-RUSSIA:STEL 0.5 mg/m3 JAN 1993 OEL-SWITZERLAND:TWA 5 mg/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 5 mg/m3 JAN 1993 OEL IN BULGARIA, COLOMBIA, JORDAN, KOREA check ACGIH TLV OEL IN NEW ZEALAND, SINGAPORE, VIETNAM check ACGIH TLV *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO ACETYLSALICYLIC ACID-air:10H TWA 5 mg/m3 REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992 NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 84517 No. of Facilities: 1746 (estimated) No. of Industries: 12 No. of Occupations: 16 No. of Employees: 10452 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X1189 No. of Facilities: 27 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 191 (estimated) No. of Female Employees: 82 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 84517 No. of Facilities: 491 (estimated) No. of Industries: 9 No. of Occupations: 22 No. of Employees: 10776 (estimated) No. of Female Employees: 6083 (estimated)

符号 GHS07
GHS07
信号词 Warning
危害声明 H302-H315-H319-H335
警示性声明 P261-P305 + P351 + P338
个人防护装备 dust mask type N95 (US);Eyeshields;Faceshields;Gloves
危害码 (欧洲) Xn:Harmful
风险声明 (欧洲) R22;R36/37/38
安全声明 (欧洲) S26-S36/37/39
危险品运输编码 UN 1851
WGK德国 1
RTECS号 VO0700000
包装等级 III
海关编码 3004909090

1.水杨酸乙酰化而得:在反应罐中加乙酐(加料量为水杨酸总量的0.7889倍),再加入三分之二量的水杨酸,搅拌升温,在81-82℃反应40-60min。降温至81-82℃保温反应2h。检查游离水杨酸合格后,降温至13℃,析出结晶,甩滤,水洗甩干,于65-70℃气流干燥,得乙酰水杨酸。

2.制法:

于干燥的反应瓶中,加入干燥的水杨酸(2)25g(0.18mol),醋酸酐38g(0.37mol),浓硫酸1mL,于60℃水浴中反应30min。冷却后倒入400mL水中,充分搅拌,过滤、水洗。用1:1的稀醋酸重结晶,得乙酰水杨酸(1)32g,收率98%。注:①也可用如下方法提纯:将粗产品溶于少量热乙醇中,再将热乙醇溶液慢慢加入2.5倍体积的热水中,形成透明溶液,慢慢冷却析出乙酰水杨酸针状结晶。

3.制法:

于反应瓶中加入干燥的水杨酸(2)25g(0.18mol),干燥的吡啶18mL,摇动使之溶解。慢慢滴加乙酰氯21g(0.28mol),反应放热,控制反应温度不超过60℃。加完后继续反应10min。冷却,倒入60mL冷水中,析出固体。抽滤、水洗,再用1:1的稀醋酸重结晶,得乙酰水杨酸(1)22g,收率67.5%。mp136~138℃(128~135℃部分分解)。

海关编码 2916310020
中文概述 2916310020 2-(乙酰氧基)苯甲酸 退税率:0.0% 监管条件:S(进出口农药登记证明)
申报要素 品名, 成分含量, 用途, 丙烯酸、丙烯酸盐或酯应报明包装
监管条件 S.进出口农药登记证明
Summary 2916310020 2-acetoxybenzoic acid